JP Morgan Chase’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$250K Buy
+12,000
New +$281K ﹤0.01% 5640
2025
Q2
– Sell
-30,000
Closed -$408K – 7206
2025
Q1
$408K Buy
+30,000
New +$575K ﹤0.01% 4893
2024
Q3
– Sell
-30,000
Closed -$697K – 7463
2024
Q2
$697K Buy
+30,000
New +$576K ﹤0.01% 4500

Other funds holding DNLI

JP Morgan Chase's DNLI Position: Q3 2026 in Review

JP Morgan Chase increased its Denali Therapeutics (DNLI) stake by 1.6% in Q3 2026, buying an estimated $106K and bringing the position to 291,531 shares worth $6.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3287.

JP Morgan Chase first reported a position in DNLI in Q1 2018 and has held it in 35 quarters since. The position peaked at $27.7M in Q4 2020. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • JP Morgan Chase held 291,531 shares of Denali Therapeutics worth $6.22M as of Q3 2026.
  • JP Morgan Chase bought 4,512 Denali Therapeutics shares in Q3 2026, an estimated $106K.
  • Denali Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #3287 holding.
  • JP Morgan Chase first reported a position in Denali Therapeutics in Q1 2018 and has held it in 35 quarters since.
  • JP Morgan Chase's Denali Therapeutics position peaked at $27.7M in Q4 2020.
  • 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.